Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct 15;27(20):5449-5451.
doi: 10.1158/1078-0432.CCR-21-2181. Epub 2021 Aug 13.

Going with the Flow: The Promise of Plasma-Only Circulating Tumor DNA Assays

Alisha Bent  1 , Scott Kopetz  2
Affiliations
Comment

Going with the Flow: The Promise of Plasma-Only Circulating Tumor DNA Assays

Alisha Bent et al. Clin Cancer Res. .

Abstract

Circulating tumor DNA (ctDNA) has emerged as a noninvasive diagnostic and prognostic tool for colorectal cancer. Here, we discuss studies that evaluate the ability of plasma-only ctDNA assays to detect minimal residual disease and the potential benefit of integration of methylation into ctDNA assays.See related articles by Parikh et al., p. 5586 and Taieb et al., p. 5638.

PubMed Disclaimer

Conflict of interest statement

Corresponding Author Disclosures/COI: Dr Kopetz has consulting or advisory roles with the following: Roche, Genentech, EMD Serono, Merck, Navire, Symphogen, Holy Stone, Healthcare, Amgen, Novartis, Lilly, Boehringer Ingelheim, Boston Biomedical, AstraZeneca/MedImmune, Bayer Health, Pierre Fabre, Redx Pharma, Ipsen, Daiichi, Sankyo, Natera, HalioDx, Lutris, Jacobio, Pfizer, Repare Therapeutics, Inivata, GlaxoSmithKline, Jazz Pharmaceuticals

Figures

Figure 1:
Figure 1:
Comparison of methylated and mutated ctDNA as utilized in the two studies of Parikh (1) and Taieb (2).
See this image and copyright information in PMC

Comment on

References

    1. Parikh AR, Van Seventer EE, Siravegna G, Hartwig AV, Jaimovich A, He Y, et al. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clin Cancer Res. 2021. Apr 29. doi: 10.1158/1078-0432.CCR-21-0410. Epub ahead of print. - DOI - PMC - PubMed
    1. Taieb J, Taly V, Henriques J, Bourreau C, Mineur L, Bennouna J, et al. Prognostic value and relation with adjuvant treatment duration of ctDNA in stage III colon cancer: a post-hoc analysis of the PRODIGE-GERCOR IDEA-France trial. Clin Cancer Res 2021;0271.2021. - PubMed
    1. Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017. Mar;15(3):370–398. doi: 10.6004/jnccn.2017.0036. - DOI - PubMed
    1. Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017. Apr;17(4):223–238. doi: 10.1038/nrc.2017.7. Epub 2017 Feb 24. - DOI - PubMed
    1. Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019. Aug 1;5(8):1124–1131.doi: 10.1001/jamaoncol.2019.0528. Erratum in: JAMA Oncol. 2019 Jun 13v - DOI - PMC - PubMed

Publication types